BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 23426430)

  • 21. Identification of a novel CD8+ T cell epitope derived from cancer-testis antigen MAGE-4 in oesophageal carcinoma.
    Wu ZY; Gao YF; Wu YH; Liu W; Sun M; Zhai MX; Qi YM; Ye Y
    Scand J Immunol; 2011 Dec; 74(6):561-7. PubMed ID: 21815906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of HLA-A*0201-restricted CD8+ T-cell epitope C₆₄₋₇₂ from hepatitis B virus core protein.
    Liu Q; Zheng Y; Yu Y; Tan Q; Huang X
    Int Immunopharmacol; 2012 Jun; 13(2):141-7. PubMed ID: 22480777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
    Olson BM; Frye TP; Johnson LE; Fong L; Knutson KL; Disis ML; McNeel DG
    Cancer Immunol Immunother; 2010 Jun; 59(6):943-53. PubMed ID: 20140431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
    May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.
    Vikman S; Giandomenico V; Sommaggio R; Oberg K; Essand M; Tötterman TH
    Cancer Immunol Immunother; 2008 Mar; 57(3):399-409. PubMed ID: 17717663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses.
    Snyder JT; Belyakov IM; Dzutsev A; Lemonnier F; Berzofsky JA
    J Virol; 2004 Jul; 78(13):7052-60. PubMed ID: 15194781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1.
    Ishizaki H; Tsunoda T; Wada S; Yamauchi M; Shibuya M; Tahara H
    Clin Cancer Res; 2006 Oct; 12(19):5841-9. PubMed ID: 17020992
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identification of a human CD8+ T lymphocyte neo-epitope created by a ras codon 12 mutation which is restricted by the HLA-A2 allele.
    Bergmann-Leitner ES; Kantor JA; Shupert WL; Schlom J; Abrams SI
    Cell Immunol; 1998 Aug; 187(2):103-16. PubMed ID: 9732698
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel CD8+ T cell-based vaccine stimulates Gp120-specific CTL responses leading to therapeutic and long-term immunity in transgenic HLA-A2 mice.
    Nanjundappa RH; Wang R; Xie Y; Umeshappa CS; Xiang J
    Vaccine; 2012 May; 30(24):3519-25. PubMed ID: 22484292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sustained CD8+ T-cell immune response to a novel immunodominant HLA-B*0702-associated epitope derived from an Epstein-Barr virus helicase-primase-associated protein.
    Turcanová V; Höllsberg P
    J Med Virol; 2004 Apr; 72(4):635-45. PubMed ID: 14981767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HLA anchor optimization of the melan-A-HLA-A2 epitope within a long peptide is required for efficient cross-priming of human tumor-reactive T cells.
    Chauvin JM; Larrieu P; Sarrabayrouse G; Prévost-Blondel A; Lengagne R; Desfrançois J; Labarrière N; Jotereau F
    J Immunol; 2012 Mar; 188(5):2102-10. PubMed ID: 22291187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Umbilical cord blood T cells respond against the Melan-A/MART-1 tumor antigen and exhibit reduced alloreactivity as compared with adult blood-derived T cells.
    Merindol N; Grenier AJ; Caty M; Charrier E; Duval A; Duval M; Champagne MA; Soudeyns H
    J Immunol; 2010 Jul; 185(2):856-66. PubMed ID: 20543110
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Identification and characterization of HLA-class-I-restricted T-cell epitopes in the putative tumor-associated antigens P21-activated serin kinase 2 (PAK2) and cyclin-dependent kinase inhibitor 1A (CDKN1A).
    Li G; Hundemer M; Wolfrum S; Ho AD; Goldschmidt H; Witzens-Harig M
    Ann Hematol; 2006 Sep; 85(9):583-90. PubMed ID: 16718496
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA-A*0201-restricted CD8+ cytotoxic T lymphocyte epitopes identified from herpes simplex virus glycoprotein D.
    Chentoufi AA; Zhang X; Lamberth K; Dasgupta G; Bettahi I; Nguyen A; Wu M; Zhu X; Mohebbi A; Buus S; Wechsler SL; Nesburn AB; BenMohamed L
    J Immunol; 2008 Jan; 180(1):426-37. PubMed ID: 18097044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A naturally processed epitope on rotavirus VP7 glycoprotein recognized by HLA-A2.1-restricted cytotoxic CD8+ T cells.
    Wei J; Li J; Zhang X; Tang Y; Wang J; Wu Y
    Viral Immunol; 2009 Jun; 22(3):189-94. PubMed ID: 19435415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward the development of multi-epitope p53 cancer vaccines: an in vitro assessment of CD8(+) T cell responses to HLA class I-restricted wild-type sequence p53 peptides.
    Sakakura K; Chikamatsu K; Furuya N; Appella E; Whiteside TL; Deleo AB
    Clin Immunol; 2007 Oct; 125(1):43-51. PubMed ID: 17631051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.
    Liu F; Zhang H; Shen D; Wang S; Ye Y; Chen H; Pang X; Song Q; He P
    J Gastroenterol; 2014 Mar; 49(3):419-26. PubMed ID: 23604623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.